Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-11
2011-01-11
Chung, Susannah (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S418000, C548S483000, C548S484000, C548S486000
Reexamination Certificate
active
07868034
ABSTRACT:
This invention is directed to indolone derivatives which are antagonists or the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 4874687 (1989-10-01), Itabashi et al.
patent: 4921503 (1990-05-01), Anderson et al.
patent: 4946956 (1990-08-01), Wheeler
patent: 5017466 (1991-05-01), Kobayashi et al.
patent: 5198461 (1993-03-01), Watjen et al.
patent: 5547949 (1996-08-01), Maho et al.
patent: 5728704 (1998-03-01), Mylari et al.
patent: 5801150 (1998-09-01), Caillot et al.
patent: 5840893 (1998-11-01), Bukrinsky et al.
patent: 6287788 (2001-09-01), Bard et al.
patent: 6329197 (2001-12-01), Bard et al.
patent: 6368812 (2002-04-01), Bard et al.
patent: 7081470 (2006-07-01), Konkel et al.
patent: 7166635 (2007-01-01), Konkel et al.
patent: 2003/0027254 (2003-02-01), Bard et al.
patent: 2003/0078271 (2003-04-01), Blackburn et al.
patent: 2003/0082641 (2003-05-01), Bard et al.
patent: 2003/0119096 (2003-06-01), Bard et al.
patent: 2004/0082615 (2004-04-01), Konkel et al.
patent: 2004/0102507 (2004-05-01), Konkel et al.
patent: 2004/0127502 (2004-07-01), Blackburn et al.
patent: 2005/0148635 (2005-07-01), Konkel et al.
patent: 0359465 (1990-03-01), None
patent: 0363002 (1990-04-01), None
patent: 0640599 (1995-03-01), None
patent: 0667340 (1995-08-01), None
patent: 0788890 (1997-08-01), None
patent: 0945442 (1999-09-01), None
patent: 0972770 (2000-01-01), None
patent: 1477349 (2000-06-01), None
patent: 11158073 (1999-06-01), None
patent: 2000075449 (2000-03-01), None
patent: 9815570 (1998-04-01), None
patent: 9941253 (1999-08-01), None
patent: 9950250 (1999-10-01), None
patent: 9325539 (1999-12-01), None
patent: 9965875 (1999-12-01), None
patent: 0002865 (2000-01-01), None
patent: 02060392 (2002-07-01), None
1-Phenyl-3-{[3-(triflouromethyl)phenyl]imino}-1,3-dihydro-2H-indol-2-one, Bionet Research Ltd. Catalog #11L-312S.
Hokfelt, T., et al. Galanin and NPY, Two Peptides with Multiple Putative Roles in the nervous System, Horm. Metab. Reg., (1999), 33:330-334.
Razani, H., et al., Intraventricular Galanin Produces a Timedependent Modulation of 5-HT1A Receptors in the Dorsal Raphe of the Rat, Neuropharmacology and Neurotoxicology, (2000), 11(18): 3943-3948.
Stolle, et al., Abstract (Journal fuer Praktische Chemie (Leipzig), 1930, vol. 128, pp. 1-434).
Kisteneve, et al., Abstract (Zhurnal Obshchei Khimii, 1956, vol. 26, pp. 1169-1175).
Chemical Abstracts Registry No. 61038-64-0.
Chemical Abstracts Registry No. 41230-77-7.
Chemical Abstracts Registry No. 130186-15-1.
Chemical Abstracts Registry No. 130186-16-2.
Chemical Abstracts Registry No. 130186-17-3.
Chemical Abstracts Registry No. 130186-18-4.
Chemical Abstracts Registry No. 130186-21-9.
Chemical Abstracts Registry No. 130270-13-2.
Chemical Abstracts Registry No. 133939-75-0.
Chemical Abstracts Registry No. 56984-58-8.
Chemical Abstracts Registry No. 77910-42-0.
Chemical Abstracts Registry No. 70010-41-2.
Chemical Abstracts Registry No. 189264-35-5.
Chemical Abstracts Registry No. 88291-04-7.
Chemical Abstracts Registry No. 88291-07-0.
Chemical Abstracts Registry No. 154118-05-5.
Chemical Abstracts Registry No. 155717-81-0.
Chemical Abstracts Registry No. 155717-82-1.
Chemical Abstracts Registry No. 159967-24-5.
Chemical Abstracts Registry No. 138601-94-2.
Chemical Abstracts Registry No. 136647-69-3.
Chemical Abstracts Registry No. 136647-72-8.
Chemical Abstracts Registry No. 77297-28-0.
Chemical Abstracts Registry No. 43002-26-2.
Chemical Abstracts Registry No. 303984-69-2.
Chemical Abstracts Registry No. 122725-53-5.
Chemical Abstracts Registry No. 122803-89-8.
Chemical Abstracts Registry No. 303149-10-2.
Chemical Abstracts Registry No. 303149-08-8.
Chemical Abstracts Registry No. 303149-06-6.
Chemical Abstracts Registry No. 303984-47-6.
Chemical Abstracts Registry No. 303149-14-6.
Chemical Abstracts Registry No. 303149-12-4.
Chemical Abstracts Registry No. 303984-51-2.
Chemical Abstracts Registry No. 303984-49-8.
Chemical Abstracts Registry No. 303984-48-7.
Chemical Abstracts Registry No. 303984-52-3.
Chemical Abstracts Registry No. 303984-60-3.
Chemical Abstracts Registry No. 303984-61-4.
Chemical Abstracts Registry No. 303984-62-5.
Chemical Abstracts Registry No. 33984-68-1.
U.S. Appl. No. 10/638,242 by Konkel, Blackburn and Wetzel.
Johnathan Clayden, Nick Greeves, Stuart Warren & Peter Wothers, Organic Chemistry 28 (1st ed. 2001).
Konkel Michael
Talisman Jamie
Werzel John M.
Chung Susannah
H. Lundbeck A/S
Pelto Don J.
Sheppard Mullin Richter & Hampton LLP
LandOfFree
Use of GALR3 receptor antagonists for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of GALR3 receptor antagonists for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of GALR3 receptor antagonists for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2660707